Application of mogroside IV-E in preparation of product for improving skin aging and / or promoting skin repair

Abstract

The invention relates to application of mogroside IV-E in preparation of a product for improving skin aging and / or promoting skin repair. A large number of experiments prove that mogroside IV-E can improve skin aging and promote skin repair and has good safety, specifically, mogroside IV-E can activate expression of SIRT1 protein, and the mogroside IV-E can inhibit skin aging and promote skin repair. The synthesis of elastin can be promoted, so that the reduction of the content of elastin in skin keratinocytes caused by ultraviolet aging stimulation is remarkably inhibited, and the healing capability of cell scratches can be promoted. In conclusion, the mogroside IV-E has great clinical application prospect and value in preparation of anti-aging and repairing products.

Description

Technical Field

[0001] The present application relates to the field of biomedical technologies, and particularly to the application of mogroside IV-E in the preparation of products for improving skin aging and / or promoting skin repair. Background Art

[0002] There are generally two core types of skin aging. One is endogenous aging, which is mainly dominated by genetic genes, manifested as the gradual decline of skin metabolic function, the reduction of collagen and elastin synthesis, and the loss of subcutaneous fat, including the loss of collagen, the slowdown of epidermal renewal, and the reduction of sebum secretion. The other is exogenous aging, which is mainly affected by the external environment and accounts for more than 80% of the factors causing skin aging. The core mechanisms include photoaging, oxidative stress, and glycation reaction. It is mainly due to the destruction of collagen fibers by ultraviolet rays, the overexpression of metalloproteinases induced, resulting in skin relaxation and wrinkles; free radicals attacking cell membranes and mitochondrial DNA, accelerating cell apoptosis; advanced glycation end products cross-linking with collagen, making the skin turn yellow and lose elasticity, etc. Summary of the Invention

[0003] Based on this, the object of the present application includes providing the application of mogroside IV-E in the preparation of products for improving skin aging and / or promoting skin repair.

[0004] The technical solution of the present application is as follows:

[0005] The present invention provides the application of mogroside IV-E in the preparation of products for improving skin aging and promoting skin repair.

[0006] In one embodiment, the product includes cosmetics, foods or drugs.

[0007] In one embodiment, the cosmetics include one or more of lotion, cream, emulsion, essence, facial mask and eye cream.

[0008] In one embodiment, the foods include one or more of functional foods, beverages, health products and nutritional supplements.

[0009] In one embodiment, the dosage forms of the drugs include oral solution, liquid suspension, powder, tablet, capsule, powder, mixture, pill, granule, syrup, plaster, suppository, aerosol, ointment or injection.

[0010] In one embodiment, the product further includes excipients.

[0011] In one embodiment, the administration methods of the product include oral administration and / or external application.

[0012] In one embodiment, the external application includes topical transdermal administration and / or systemic transdermal administration.

[0013] In one embodiment, improving skin aging and promoting skin repair means activating the expression of SIRT1.

[0014] In one embodiment, improving skin aging and promoting skin repair means promoting the expression of elastin; and / or

[0015] Improving skin aging and promoting skin repair means promoting cell healing.

[0016] Compared with the prior art, the present application has the following beneficial effects:

[0017] The inventors of the present application have confirmed through a large number of experiments that mogroside IV-E can improve skin aging and promote skin repair, and has good safety. Specifically, mogroside IV-E can activate the expression of SIRT1 protein, can promote the synthesis of elastin and thus significantly inhibit the decrease in the content of elastin in human skin keratinocytes caused by ultraviolet light aging stimulation, and is superior to the existing activator resveratrol; mogroside IV-E can promote the healing ability of cell scratches. In summary, mogroside IV-E has great clinical application prospects and value in the preparation of anti-aging and repair products. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the specific embodiments of the present application or the technical solutions in the prior art, the following will briefly introduce the drawings required for the description of the specific embodiments or the prior art. Obviously, the drawings in the following description are some embodiments of the present application. For those of ordinary skill in the art, without creative efforts, other drawings can also be obtained based on these drawings.

[0019] Figure 1 It is a graph showing the toxicity test results of mogroside IV-E on human skin immortalized keratinocytes in Example 1.

[0020] Figure 2 It is a graph showing the activation effect of mogroside IV-E on SIRT1 protein in Example 1.

[0021] Figure 3 It is a graph showing the promoting effect of mogroside IV-E on the expression of elastin in Example 1.

[0022] Figure 4 It is a graph showing the promoting effect of mogroside IV-E on the healing of scratches on human skin immortalized keratinocytes in Example 1. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0023] To make the above objects, features, and advantages of the present application more apparent and understandable, the following provides a detailed description of the specific embodiments of the present application. Many specific details are set forth in the following description to facilitate a full understanding of the present application. However, the present application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without departing from the connotation of the present application. Therefore, the present application is not limited by the specific embodiments disclosed below.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application belongs. The terms used in the description of the present application herein are only for the purpose of describing specific embodiments and are not intended to limit the present application.

[0025] Unless otherwise stated or there is a contradiction, the terms or phrases used herein have the following meanings:

[0026] As used herein, "pharmaceutically acceptable" refers to those ligands, materials, compositions, and / or dosage forms that are suitable for administration to a patient within the scope of reasonable medical judgment and are commensurate with a reasonable benefit / risk ratio.

[0027] As used herein, "pharmaceutically acceptable salt" refers to a salt formed by any compound in the indicated structure with an acid or a base that is suitable for use as a drug. Pharmaceutically acceptable salts include inorganic salts and organic salts. Among them, one type of salt is the salt formed by the compounds of the present application with an acid. Acids suitable for forming salts include, but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, glutamic acid. Another type of salt is the salt formed by the compounds of the present application with a base. Bases suitable for forming salts include, but are not limited to: alkali metal salts (such as sodium salts or potassium salts), alkaline earth metal salts (such as magnesium salts or calcium salts), ammonium salts (such as lower alkanolammonium salts and other pharmaceutically acceptable amine salts), such as methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts, and amine salts formed by morpholine, piperazine, and lysine, respectively.

[0028] As used herein, "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. As used herein, the phrase "pharmaceutically acceptable carrier" includes buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like that are compatible with the administration of the drug. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients in the formulation and not injurious to the patient. Suitable examples include, but are not limited to: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch, potato starch and substituted or unsubstituted β-cyclodextrin; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer; (21) other non-toxic compatible substances employed in pharmaceutical formulations.

[0029] As used herein, "one or more" refers to any one, any two or any two or more of the listed items.

[0030] As used herein, the optional scope of "and / or", "or / and", "and / or" includes any one of two or more related listed items, and also includes any and all combinations of the related listed items, and the said any and all combinations include combinations of any two related listed items, any more related listed items, or all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", "and / or", it should be understood that in this application, this technical solution undoubtedly includes the technical solution connected by "logical AND", and also undoubtedly includes the technical solution connected by "logical OR". For example, "A and / or B" includes three parallel solutions: A, B, and A + B. Another example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, D (that is, the technical solution connected by "logical OR"), and also includes any and all combinations of A, B, C, D, that is, includes combinations of any two or any three of A, B, C, D, and also includes the four-item combination of A, B, C, D (that is, the technical solution connected by "logical AND").

[0031] In this document, terms such as "further", "even further", "especially", etc. are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of this application.

[0032] In this application, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are considered continuous and include the minimum and maximum values of the range, as well as every value between such minimum and maximum values. Further, when the range refers to integers, it includes every integer between the minimum and maximum values of the range. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all sub-ranges subsumed therein.

[0033] This document specifically discloses only some numerical ranges. However, any lower limit can be combined with any upper limit to form a range not explicitly recited; and any lower limit can be combined with other lower limits to form a range not explicitly recited, and similarly any upper limit can be combined with any other upper limit to form a range not explicitly recited. In addition, each individually disclosed point or single numerical value itself can be used as a lower limit or upper limit and combined with any other point or single numerical value or with other lower limits or upper limits to form a range not explicitly recited. The use of numerical ranges expressed by endpoints includes all numbers within the range and any ranges within that range. For example, 1 to 5 includes 1, 1.1, 1.3, 1.5, 2, 2.75, 3, 3.80, 4, and 5, etc.

[0034] In this application, for the percentage content involved, unless otherwise specified, for solid-liquid mixtures and solid-solid mixtures, it refers to the mass percentage, and for liquid-liquid mixtures, it refers to the volume percentage.

[0035] In this application, for the percentage concentration involved, unless otherwise specified, it refers to the final concentration. The final concentration refers to the proportion of the added component in the system after adding this component.

[0036] For the temperature parameters in this application, unless otherwise specifically limited, it allows both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows the temperature to fluctuate within the accuracy range controlled by the instrument. It is allowed to fluctuate within ranges such as ±5°C, ±2°C, ±1°C, ±0.5°C, ±0.4°C, ±0.3°C, ±0.2°C, ±0.1°C. Normal temperature or room temperature in this application refers to no temperature control operation, generally referring to 4°C to 35°C, preferably 20 ± 5°C.

[0037] In this application, for the technical features described in an open-ended manner, it includes both the closed technical solutions composed of the listed features and the open technical solutions including the listed features.

[0038] Silent information regulator 1 (SIRT1) belongs to the Sirtuin family and is a class III histone deacetylase that depends on NAD + . It mainly participates in the regulation of processes such as oxidative stress, inflammatory response, cell metabolism, and aging by deacetylating target proteins (including histones and non-histones). SIRT1 scavenges ROS mainly by activating transcription factors such as FOXO3a and PGC-1α, upregulating the expression of SOD (superoxide dismutase) and CAT (catalase), and reducing the accumulation of reactive oxygen species induced by ultraviolet (UV) light. SIRT1 anti-inflammatory mainly deacetylates the NF-κB p65 subunit (at the Lys310 site), blocks its nuclear translocation, and reduces the release of pro-inflammatory factors (such as TNF-α and IL-6).

[0039] Mogroside IV-E is a triterpenoid glycoside compound isolated from the extract of Siraitia grosvenorii. It belongs to non-saccharide natural sweeteners and has pharmacological activities such as antioxidant, anti-cancer, blood glucose regulation, anti-inflammatory liver protection, and immune regulation. Its chemical formula is C 54 H 92 O 24 , and the structural formula is as follows: .

[0040] Studies have shown that Mogroside IV-E has the effects of inhibiting cell proliferation and apoptosis, and can promote the apoptosis of lung cancer (A549) and colon cancer (HCT-116) cells by activating the Caspase-3 / 9 pathway. In a breast cancer (MCF-7) model, Mogroside IV-E can block the cell cycle at the G0 / G1 phase by inhibiting the STAT3 and NF-κB signaling pathways. In a lipopolysaccharide (LPS)-induced macrophage model, Mogroside IV-E can reduce the expression of TNF-α, IL-6, and IL-1β, and inhibit the phosphorylation of NF-κB, achieving an inhibitory effect on inflammatory factors. However, there is currently no study showing that Mogroside IV-E can affect the expression of the aging-related protein SIRT1 and its function in skin protection.

[0041] Based on this, the present invention provides the use of Mogroside IV-E in the preparation of products for improving skin aging and / or promoting skin repair.

[0042] In some examples, the product further includes excipients.

[0043] In some examples, the administration methods of the product include oral administration and / or topical application.

[0044] In some of these examples, the topical application includes topical transdermal administration and / or systemic transdermal administration.

[0045] In some of these examples, the product includes cosmetics, food, or drugs.

[0046] In some of these examples, the cosmetics include one or more of lotion, cream, emulsion, essence, facial mask, and eye cream.

[0047] In some of these examples, the food includes one or more of functional food, beverage, health product, and nutritional supplement.

[0048] In some of these examples, the drug includes the active ingredient mogroside IV-E, and pharmaceutically acceptable excipients. Further, the pharmaceutically acceptable excipients include, but are not limited to, pharmaceutically acceptable salts, diluents, wetting agents, binders, disintegrants, lubricants, color, flavor, and fragrance regulators, solvents, solubilizers, cosolvents, emulsifiers, antioxidants, metal chelating agents, inert gases, preservatives, local anesthetics, pH regulators, isotonic or isosmotic regulators, etc.

[0049] In some of these examples, the dosage forms of the drug include oral solution, liquid suspension, powder, tablet, capsule, powder, mixture, pill, granule, syrup, patch, suppository, aerosol, ointment, or injection. It can be understood that the drugs of the present application can be added with different pharmaceutically acceptable excipients to prepare suitable clinical dosage forms, and these clinical dosage forms include, but are not limited to, the dosage forms described herein.

[0050] In some of these examples, the drug can be administered by a suitable administration route according to clinical needs. It can be understood that the administration routes of the drug include intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration, or transdermal administration.

[0051] In some of these examples, improving skin aging includes one or more of improving skin photoaging, improving wrinkles, improving age spots, and improving skin laxity.

[0052] In some of these examples, improving skin aging and / or promoting skin repair means activating the expression of SIRT1. Specifically, mogroside IV-E can be used as a deacetylase SIRT1 activator to increase the activity of SIRT1 protein, and it is experimentally demonstrated for the first time in the present application that mogroside IV-E can activate the expression of SIRT1 protein, and the effect is better than that of the recognized activator resveratrol.

[0053] In some of these examples, improving skin aging and / or promoting skin repair refers to promoting the expression of elastin. Specifically, for the first time in this application, it has been experimentally demonstrated that mogroside IV-E can promote the synthesis of elastin, and thus significantly inhibit the decrease in the content of elastin in skin keratinocytes caused by ultraviolet light aging stimulation.

[0054] In some of these examples, improving skin aging and / or promoting skin repair refers to promoting cell healing. Specifically, for the first time in this application, it has been experimentally demonstrated that mogroside IV-E can promote the healing ability of cell scratches, promote skin wound healing, and accelerate repair.

[0055] In summary, this application discloses the use of a novel SIRT1 activator in resisting skin photoaging. The compound consists of mogroside IV-E. This compound can simultaneously activate the aging-related protein SIRT1, promote the expression of elastin in human immortalized skin keratinocytes, promote the healing ability of skin cells, and has no obvious side effects. The compound of the present invention can be used for the preparation of applications related to skin anti-aging.

[0056] The following further explanations are provided in combination with specific examples. For the raw materials involved in the following specific examples, unless otherwise specified, they can all be obtained commercially; for the instruments used, unless otherwise specified, they can all be obtained commercially; for the processes involved, unless otherwise specified, they are all the conventional selections of those skilled in the art.

[0057] Some of the raw materials used in the examples are as follows:

[0058] Human immortalized skin keratinocytes (HaCaT) were purchased from Zhejiang Meisen Cell Technology Co., Ltd.

[0059] Resveratrol and Mogroside IV-E were purchased from MedChemExpress.

[0060] The positive control compound selected in this article is resveratrol, a polyphenolic substance also known as piceatannol, with the chemical formula C 14 H 12O3 is a natural antitoxin produced by various plants when stimulated by the external environment. Resveratrol has the ability to scavenge free radicals and inhibit their generation, and at the same time can regulate the activities related to antioxidant enzymes, thus preventing cell aging caused by lipid peroxides, fundamentally solving skin damage problems, delaying skin aging, and achieving the effect of reverse growth. In addition, resveratrol can also reduce the formation of melanin by inhibiting the activities of melanocytes and tyrosinase, achieving the effect of whitening the skin. As a potent SIRT1 inducer, resveratrol can activate acetylase and increase the expression of SIRT1 in tissues such as the brain, heart, intestine, kidney, muscle, and fat. It can also promote the proliferation of elastin, fibroblasts, and epidermal keratinocytes, enhance skin elasticity, and significantly extend lifespan by 50%. Research shows that resveratrol not only helps support wound healing and reduce the formation of excessive scars, but also effectively prevents the aging phenomenon of the skin caused by ultraviolet light.

[0061] The following are specific examples.

[0062] Example 1

[0063] I. Cell culture: Human immortalized keratinocytes (HaCaT) were used in the experiment. They were thoroughly mixed with DMEM complete medium and inoculated at a density of 6×10 5 cells in a 6-cm cell culture dish, and then placed in a cell culture incubator at 37°C, 5% CO2, and saturated humidity for culture. The cells adhered and grew. When they grew to cover 80% of the bottom area of the culture dish, subculture was started. When subculturing, the original culture medium was aspirated, the cells were washed twice with PBS, digested with 0.25% trypsin, and left standing in the cell culture incubator for 7 minutes until the cells shrank, became round, and gradually detached from the culture flask. Then, a complete medium with twice the volume of trypsin was added to stop digestion. The cell suspension was collected, centrifuged, resuspended with an appropriate amount of complete medium, counted, and then cells at a certain concentration were transferred to a new culture dish, and 10 mL of culture medium was added, and the cells were mixed evenly to spread them evenly in the dish.

[0064] II. Cell drug treatment: When the cells grew to the logarithmic growth phase, they were digested and counted, and then inoculated at a density of 6×10 5 cells in a 6-cm culture dish (5×10 5 cells in a 6-well plate; 1×10 4Placed in a 96-well plate and cultured in a CO2 incubator at 37°C, 5% CO2, and saturated humidity for 24 h. After the cells adhered, the model group (ultraviolet group) and the drug treatment group were irradiated with ultraviolet light using a UVA 95% + UVB 5% ultraviolet aging box to simulate natural sunlight for 90 min, and then the culture medium was changed. The model group was added with an equal amount of complete culture medium, and the drug treatment group was added with the complete culture medium containing the corresponding concentration of each drug, and then continued to be cultured in the cell culture incubator until the required time for subsequent experimental detection. The treatment method for the control group was: no ultraviolet irradiation and drug treatment, and the operation was similar to that of the model group after 90 minutes of ultraviolet irradiation, and the drug-free culture medium was replaced synchronously.

[0065] The drugs used in the drug treatment group included resveratrol solution and Mogroside IV-E solution. The preparation methods were as follows: Resveratrol and Mogroside IV-E were respectively dissolved in dimethyl sulfoxide (DMSO) to prepare a stock solution of 10 mM, and diluted according to their respective working concentrations in the experiment.

[0066] III. Safety detection of drugs: When the cell density of the cells treated with drugs in the 96-well plate reached about 80% of the bottom area of the culture dish, the original culture medium after drug treatment was replaced according to the ratio of CCK-8 reagent to cell culture medium (1:10), and continued to be cultured in a CO2 incubator at 37°C, 5% CO2, and saturated humidity for 2 h. The absorbance was measured at a wavelength of 450 nm to calculate the effect of the drug on the cell survival rate, and then the toxicity of the drug was judged. The results are as Figure 1 shown. The results showed that Mogroside IV-E had good safety within the concentration range of 0 - 3.5 μM, had no significant effect on cell viability, and could be regarded as a safe concentration range.

[0067] IV. Detection of the effects of drugs on the expression of senescence-related protein SIRT1 and elastin: After ultraviolet-stimulated cell modeling, the drug treatment group was added with Mogroside IV-E (1 μM) and resveratrol (1 μM) respectively, and human immortalized keratinocytes were treated for 24 h. Then the cells were collected and proteins were extracted for WB (Western Blot) experiments. In this application, SIRT1 and elastin were detected. By comparing with the control group, it could be judged whether the model group was successfully established. If the expressions of SIRT1 and elastin in the model group were significantly lower than those in the control group, the model was successfully established, otherwise it was not. At the same time, the expressions of SIRT1 and elastin in the drug treatment group were compared with those in the model group to judge the activation effect of the drug on SIRT1 and the promotion of elastin expression.

[0068] The results are as Figure 2 - Figure 3As shown, the results indicate that Mogroside IV-E can significantly activate the expression of SIRT1 and has a significant promoting effect on the synthesis of elastin. At the same time, compared with the positive control group of resveratrol at the same concentration, the activation effect on SIRT1 is stronger, and the promoting effect on elastin expression is stronger.

[0069] V. Detection of the effect of the drug on the wound healing ability of cell scratches: Inoculate cells in a 6-well plate (5×10 5 cells / well) and culture them into a monolayer. When the cell confluence rate reaches 100%, use a UVA95%+UVB5% ultraviolet aging box to simulate natural light ultraviolet irradiation for 90 min and then change the medium. Scratch the surface of the monolayer cells with a 200 μL sterile pipette tip, and wash the floating cells remaining in the well with PBS. Take a photo under the microscope to record the area of the scratched area. In the drug treatment groups, add Mogroside IV-E (1 μM) and resveratrol (1 μM) respectively, and use cell culture medium without fetal bovine serum to culture and treat human immortalized keratinocytes for 24 h. After the culture is completed, take a photo to record the area of the scratched area at 24 h.

[0070] The results are as Figure 4 shown. The results indicate that after ultraviolet irradiation, the wound healing ability of cell scratches is significantly reduced, while both Mogroside IV-E and resveratrol can promote the wound healing ability of cell scratches under ultraviolet irradiation, and the healing effect of Mogroside IV-E is higher than that of the positive control group of resveratrol.

[0071] In summary, the following conclusions can be obtained through the effect experiment:

[0072] (1) It is first discovered in this application that the compound Mogroside IV-E can activate the expression of SIRT1 protein and is superior to the recognized activator resveratrol;

[0073] (2) It is first discovered in this application that the compound Mogroside IV-E can significantly inhibit the decrease in the content of elastin in skin keratinocytes caused by ultraviolet light aging stimulation;

[0074] (3) It is first discovered in this application that the compound Mogroside IV-E can promote the wound healing ability of cell scratches.

[0075] The technical features of the above-described embodiments can be combined arbitrarily. For the sake of brevity of description, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, it should be considered as the scope described in this specification.

[0076] The above-described embodiments merely represent several implementation manners of the present application. The description is relatively specific and detailed, but it should not be construed as a limitation on the scope of the patented application. It should be noted that for those of ordinary skill in the art, without departing from the concept of the present application, several modifications and improvements can be made, and these all fall within the protection scope of the present application. In addition, it should be understood that after reading the above teachings of the present application, those skilled in the art can make various changes or modifications to the present application, and the equivalent forms obtained also fall within the protection scope of the present application. It should also be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning, or limited experiments based on the technical solutions provided by the present application are all within the protection scope of the appended claims of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the appended claims, and the specification can be used to interpret the content of the claims.

Claims

1. Application of mogroside IV-E in the preparation of products for improving skin aging and / or promoting skin repair.

2. The use according to claim 1, characterized in that: The product includes a cosmetic, a food or a medicine.

3. The use according to claim 2, characterized in that: The cosmetics include one or more of lotion, cream, emulsion, essence, facial mask and eye cream.

4. The use according to claim 2, characterized in that: The food includes one or more of functional food, beverage, health product and nutritional supplement.

5. The use according to claim 2, characterized in that: The dosage form of the drug includes oral solution, liquid suspension, powder, tablet, capsule, powder, mixture, pill, granule, syrup, plaster, suppository, aerosol, ointment or injection.

6. The use according to any one of claims 1 to 5, characterized in that: The product also includes auxiliary materials.

7. The use according to any one of claims 1 to 5, characterized in that: The administration of the product includes oral administration and / or topical administration.

8. The use according to claim 7, characterized in that: The external application includes local transdermal administration and / or systemic transdermal administration.

9. The use according to any one of claims 1 to 5, characterized in that: Improving skin aging and / or promoting skin repair refers to activating the expression of SIRT1.

10. The use according to any one of claims 1 to 5, characterized in that: Improving skin aging and / or promoting skin repair means promoting the synthesis of elastin; and / or Improving skin aging and / or promoting skin repair means promoting cellular healing.

Images